National Institutes of Health: Neoplasms, Germ Cell and Embryonal trials

The registry lists 31 Neoplasms, Germ Cell and Embryonal studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 24Phase 2 9No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesTerminatedNCT02859415Phase 1/2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell TumorsCompletedNCT00957905Phase 2Results posted
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary MetastasectomyWithdrawnNCT02839694Phase 1
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentCompletedNCT00929903Phase 1
• Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous SystemCompletedNCT00867178Phase 1
• Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00408655Phase 1
• Sunitinib in Treating Young Patients With Refractory Solid TumorsCompletedNCT00387920Phase 1
• A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military ServicemenCompletedNCT00341588
• Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid TumorsCompletedNCT00303940Phase 1
• Combination Chemotherapy in Treating Young Patients With Advanced Solid TumorsCompletedNCT00281944Phase 1
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTerminatedNCT00042952Phase 2
• ABT-751 in Treating Young Patients With Refractory Solid TumorsCompletedNCT00036959Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to TherapyCompletedNCT00030108Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedNCT00020150Phase 1
• Stereotactic Radiosurgery in Treating Patients With Brain TumorsCompletedNCT00019578Phase 1
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1